Cancer therapies based on targeted protein degradation—lessons learned with lenalidomide
For decades, anticancer targeted therapies have been designed to inhibit kinases or other
enzyme classes and have profoundly benefited many patients. However, novel approaches …
enzyme classes and have profoundly benefited many patients. However, novel approaches …
[HTML][HTML] Cancer therapies based on targeted protein degradation—lessons learned with lenalidomide
M Jan, AS Sperling, BL Ebert - Nature reviews. Clinical oncology, 2021 - ncbi.nlm.nih.gov
For decades, anticancer targeted therapies have been designed to inhibit kinases or other
enzyme classes and have profoundly benefitted many patients. Novel approaches are …
enzyme classes and have profoundly benefitted many patients. Novel approaches are …
Cancer therapies based on targeted protein degradation-lessons learned with lenalidomide
M Jan, AS Sperling, BL Ebert - Nature reviews. Clinical …, 2021 - pubmed.ncbi.nlm.nih.gov
For decades, anticancer targeted therapies have been designed to inhibit kinases or other
enzyme classes and have profoundly benefited many patients. However, novel approaches …
enzyme classes and have profoundly benefited many patients. However, novel approaches …
Cancer therapies based on targeted protein degradation-lessons learned with lenalidomide.
M Jan, AS Sperling, BL Ebert - Nature reviews. Clinical Oncology, 2021 - europepmc.org
For decades, anticancer targeted therapies have been designed to inhibit kinases or other
enzyme classes and have profoundly benefitted many patients. Novel approaches are …
enzyme classes and have profoundly benefitted many patients. Novel approaches are …
[引用][C] Cancer therapies based on targeted protein degradation—lessons learned with lenalidomide
M Jan, AS Sperling, BL Ebert - Nature Reviews Clinical Oncology, 2021 - cir.nii.ac.jp
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
| CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
| CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
Cancer therapies based on targeted protein degradation-lessons learned with lenalidomide
M Jan, AS Sperling, BL Ebert - Nature Reviews. Clinical Oncology, 2021 - hero.epa.gov
For decades, anticancer targeted therapies have been designed to inhibit kinases or other
enzyme classes and have profoundly benefited many patients. However, novel approaches …
enzyme classes and have profoundly benefited many patients. However, novel approaches …